Spire Healthcare Group plc (LON:SPI - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as GBX 267.06 ($3.39) and last traded at GBX 266.13 ($3.38), with a volume of 210451 shares changing hands. The stock had previously closed at GBX 258.50 ($3.29).
Analyst Upgrades and Downgrades
Several analysts have issued reports on the stock. Berenberg Bank upped their price target on shares of Spire Healthcare Group from GBX 286 ($3.63) to GBX 300 ($3.81) and gave the company a "buy" rating in a report on Wednesday, April 17th. JPMorgan Chase & Co. reaffirmed an "overweight" rating and issued a GBX 344 ($4.37) price target on shares of Spire Healthcare Group in a report on Thursday, April 18th.
Check Out Our Latest Report on SPI
Spire Healthcare Group Stock Up 2.9 %
The company has a quick ratio of 0.74, a current ratio of 0.69 and a debt-to-equity ratio of 170.37. The firm has a market cap of £1.07 billion, a PE ratio of 3,800.00, a P/E/G ratio of 1.06 and a beta of 0.97. The firm's 50 day moving average is GBX 243.83 and its 200-day moving average is GBX 234.66.
Spire Healthcare Group Increases Dividend
The company also recently disclosed a dividend, which will be paid on Friday, June 21st. Investors of record on Thursday, May 23rd will be paid a dividend of GBX 2.10 ($0.03) per share. This is an increase from Spire Healthcare Group's previous dividend of $0.50. The ex-dividend date of this dividend is Thursday, May 23rd. This represents a dividend yield of 0.89%. Spire Healthcare Group's dividend payout ratio is presently 4,285.71%.
Spire Healthcare Group Company Profile
(
Get Free Report)
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Further Reading
Before you consider Spire Healthcare Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spire Healthcare Group wasn't on the list.
While Spire Healthcare Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
